CLOs on the Move

Mydecine

www.mydecine.com

 
Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine`s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mydecine.com
  • 789 West Pender Street Suite 810
    Vancouver, BC CAN V6C 1H2
  • Phone: n/a

Executives

Name Title Contact Details
Dyson Walker
 Chief Compliance Officer Profile

Similar Companies

Silk Technologies

SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company`s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.

NextImage Medical

NextImage Medical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iterion Therapeutics

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.

VelosBio

VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.